Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International AB Provides Update on FDA Application Process

09/13/2021 | 02:07am EST

Biovica International AB (publ) announced that the company’s expected timeline for its updated 510(k)-application to the US Food and Drug Administration (FDA) has been prolonged due to delay in response from FDA. As Biovica is still waiting for required feedback from the FDA the company has not been able to submit its updated application yet. This means that the company most likely will not receive an answer from the FDA before the end of September, as previously communicated. After submitting the response to the FDA, the expected outcome is either approval (clearance) or a request to submit more information.


© S&P Capital IQ 2021
All news about BIOVICA INTERNATIONAL AB (PUBL)
12/01Biovica International
AQ
12/01Q2 Interim report - Promising results published at ESMO
AQ
12/01Biovica International AB Reports Earnings Results for the Second Quarter and Six Months..
CI
12/01Biovica International AB Provides Earnings Guidance for the Full Year 2021
CI
11/24Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
AQ
11/24Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
CI
11/19Biovica International
AQ
11/19Biovica's DiviTum®TKa in three studies at SABCS 2021
AQ
11/19Biovica International AB Announces Results from Three Different Studies Using Divitum?T..
CI
11/16Biovica International
AQ
More news
Financials
Sales 2022 39,0 M 4,32 M 4,32 M
Net income 2022 -28,0 M -3,10 M -3,10 M
Net cash 2022 110 M 12,2 M 12,2 M
P/E ratio 2022 -35,6x
Yield 2022 -
Capitalization 1 002 M 111 M 111 M
EV / Sales 2022 22,9x
EV / Sales 2023 4,68x
Nbr of Employees 24
Free-Float 41,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 35,20 SEK
Average target price 103,00 SEK
Spread / Average Target 193%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors